CD5 Antigens

Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)

Also Known As:

Networked: 78 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Cogné, Michel: 1 article (08/2015)
2.	Saad, Faten: 1 article (08/2015)
3.	Denizot, Yves: 1 article (08/2015)
4.	Saintamand, Alexis: 1 article (08/2015)
5.	Raia, Maddalena: 1 article (01/2015)
6.	Sun, Yongye: 1 article (01/2015)
7.	Simeone, Luigia: 1 article (01/2015)
8.	Del Vecchio, Luigi: 1 article (01/2015)
9.	De Fanis, Umberto: 1 article (01/2015)
10.	Zhang, Xiulian: 1 article (01/2015)

Related Diseases

1.	Neoplasms (Cancer) 08/21/2015 - "In contrast, in a 3'RR-deficient background tumors more often expressed the CD5 antigen (32% vs 12%, p = 0.05) that may serve to control autoimmunity and that is suspected to play a role in leukemic transformation. " 09/01/2009 - "Six cases were confirmed to express CD5 antigen on tumor cells. " 07/01/2002 - "None of the tumor cells in the 40 cases tested expressed CD5 antigen. " 05/16/1995 - "The CD5 antigens were re-expressed at the cell surface following removal of the IT molecules from the culture medium with 1.1% of the total CD5 Ag being re-expressed per hr. When our experimental data on the kinetics of cell intoxication by the IT were corrected for the proliferative potential of the resistant and of the sensitive tumor-cell populations, it appeared that the effect of ST.I-RTA treatment on Jurkat cells was only to delay cell growth for a limited time period (20 hr) without reducing effectively the tumor-cell burden. " 10/24/1990 - "This work shows that tumor promoter agents (TPA) induce the post-translational modification of the human lymphocyte surface CD5 antigen (Tp67) in several cellular types. "
2.	Lymphoma (Lymphomas) 01/01/1998 - "In our study, virtually all malignant B-NHLs with CD5 antigen expression showed strong immunoreactivity for a commercially available anti-CD5 monoclonal antibody using CARD, whereas the majority of the same lymphomas did not label for CD5 using routine IHC without CARD amplification. " 06/01/1984 - "Cells of chronic lymphoid leukaemia and centrocytic (cleaved-cell) lymphomas frequently express T65 (T 101+ or Leu 1+) antigen which is usually found on normal or neoplastic T lymphocytes. " 11/01/1983 - "Using a frozen section immunoperoxidase staining technique, 125 lymphomas with B-cell differentiation were examined for the presence of Leu-1 antigen. " 05/01/1988 - "Anti-T1 which recognizes the CD5 antigen on most T-cell leukemias and lymphomas was used as a control antibody. " 11/01/1984 - "An increased frequency of Ig heavy chain class switching and loss of T1 antigen suggest that follicular lymphomas are at a later stage of differentiation than most centrocytic lymphomas. "
3.	B-Cell Lymphoma (Lymphoma, B Cell) 12/01/2004 - "The aim of the present study was to determine whether immunophenotypic differences could be used to distinguish between non-Hodgkin's B cell lymphoma (NHL-B) and the normal B cell subpopulation by assessing the variability in the patterns of expression of some lymphoid antigens (CD5, CD19, FMC7, CD23, CD20, CD79b, CD38, CD22, CD10, sIgkappa, sIglambda, mIgA, mIgG, mIgM, and mIgD) in specimens obtained from patients with NHL-B. " 02/01/2000 - "Assessment of the expression of antigens CD5, CD10 and CD23 can be of value in the differential diagnosis of small B-cell lymphoma. " 10/01/1998 - "We observed CD5 antigen expression in a subset of cases of intravascular large B-cell lymphoma (IVLBL), and we report here five cases. " 10/01/1998 - "Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases." 06/01/1996 - "These findings suggest that CD5 antigens may serve as valid markers for the prognosis and clinical features of B-cell lymphomas and that CD5+ B-cell lymphomas with an overall poor prognosis occurs at a relatively high frequency in Japan. "
4.	Neuroblastoma 02/15/1991 - "I-131, 3-F8, an IgG3 against the GD2 antigen of neuroblastoma, which was introduced by Cheung, and In-111 T-101, against the CD5 antigen of T-cells, which was developed by Royston, stand out because of the consistency and high concentration of radioactive targeting to human tumors in clinical trials. "
5.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/01/1999 - "Expression of the CD5 antigen by neoplastic cells often is considered a diagnostic criterion for B-cell chronic lymphocytic leukemia (B-CLL). " 09/01/1998 - "Chronic lymphocytic leukemia cell (CLL) usually (95%) express B-phenotype and the CD5 antigen which is usually present on the surface of normal T cells. " 01/01/1996 - "Although expression of the CD5 antigen is also seen in small lymphocytic lymphoma and chronic lymphocytic leukemia, MCL differs from SLL/ CLL in several ways. " 05/01/1994 - "Thus, from our present observation of an albeit limited patient population, we have found an association between VH gene family use and CD5 antigen expression in chronic B-cell leukemias. " 05/04/1992 - "Association of bone marrow growth pattern, coexpression of CD14, and B-cell CD5 antigen density in 45 B-chronic lymphocytic leukemia (B-CLL) patients."

Related Drugs and Biologics

1.	Antigens
2.	Immunoglobulin G (IgG)
3.	Immunoglobulin M (IgM)
4.	Immunoglobulins (Immunoglobulin)
5.	Immunoglobulin D (IgD)
6.	Monoclonal Antibodies
7.	Clusterin
8.	Scavenger Receptors (Scavenger Receptor)
9.	CD19 Antigens
10.	Apolipoprotein A-I (Apolipoprotein A1)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)